Aeterna Zentaris Inc. announced the clinical completion of its Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of childhood Onset Growth Hormone Deficiency ("CGHD"). The Company confirms that the last patient conducted the last study visit successfully in Europe on June 13, 2024. The study enrolled 100 subjects in Europe and North America.

The Company remains on track to report top-line data for the DETECT-trial in third quarter of 2024. The DETECT-trial is the second and final study needed evaluating the potential use of macimorelin as diagnostic test in children as agreed upon with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the Company's Pediatric Investigation Plan.